ERBC (ex CERB) has acquired RTC

The European Research Biology Center (ERBC) has acquired the Research Toxicology Center (RTC).

ERBC provides healthcare and chemical professionals a comprehensive range of experimental capabilities and services, from preclinical proof-of-concept to market of any type of drug candidate or chemical compound. Each project is managed by a study director, relying on a multi-disciplinary team of experts, notably in general pharmacology, cardiology, electrophysiology and pathophysiology, and also benefiting from a world-class academic and private network.

RTC is a fully fledged contract research laboratory located near Rome, Italy, with a track record spanning more than four decades. RTC collaborates with a large range of industrial clients including the pharmaceutical, biotech, chemical, agro-chemical and biocide industries.

Oaklins' team in France advised the buyer in this transaction.

Service

M&A buy-side

Parties

“With the help of Oaklins, we are thrilled to join forces and offer a critical mass of credible and efficient alternative to the big CROs. We are proud to be a unique European player in the field. Our partnerships with the pharma, other CROs and independent experts play a key role in driving improvements in the pharmaceutical and chemical industries, delivering better data to regulators as well as improved value to study sponsors. Oaklins' team gave us fantastic support in a complex transaction.”

Serge Richard

CEO, ERBC

Talk to the deal team

Thibaut de Monclin

Managing Partner

Paris, France
Oaklins France

View profile Get in touch

Related deals

UKAT Group has acquired Bayberry Limited

Private Equity | Healthcare

UKAT Group has acquired Bayberry Limited

UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.

Learn more

Medicija has acquired Saulės Šeimos Medicinos Centras

Healthcare

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Learn more

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Healthcare

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Learn more